Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.63
+1.78 (1.75%)
At close: Aug 14, 2026, 4:00 PM EDT
103.58
-0.05 (-0.05%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Spyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9,1372,5421,36777528234
Market Cap Growth
852.02%85.99%76.31%2701.10%-88.19%-37.90%
Enterprise Value
7,9922,2121,108959-41127
Last Close Price
103.6332.7623.2821.5211.25118.75
PS Ratio
---874.9111.8812.50
PB Ratio
9.563.552.644.210.552.79
P/TBV Ratio
9.574.543.78-0.552.79
EV/Sales Ratio
---1082.03-6.78
Debt / Equity Ratio
----0.090.07
Net Debt / Equity Ratio
-1.04-1.06-1.16-1.84-1.01-1.04
Net Debt / EBITDA Ratio
--2.902.900.611.37
Net Debt / FCF Ratio
5.484.473.833.400.641.62
Asset Turnover
---0.000.030.14
Quick Ratio
18.2312.9411.1610.613.834.66
Current Ratio
18.5313.2511.2610.684.254.91
Return on Equity (ROE)
-22.98%-25.17%-59.28%-289.17%-124.87%-58.81%
Return on Assets (ROA)
-19.81%-19.80%-27.43%-35.60%-58.53%-30.22%
Return on Capital Employed (ROCE)
-24.50%-30.50%-37.60%-38.00%-150.10%-73.10%
Earnings Yield
-1.64%-6.11%-15.22%-43.70%-302.87%-28.09%
FCF Yield
-2.29%-6.66%-11.52%-12.89%-289.74%-23.17%
Buyback Yield / Dilution
-31.80%-36.21%-581.85%-104.59%-28.19%-23.18%
SEC Filings: 10-K · 10-Q